Glecirasib Appears Safe, Effective in KRAS G12C-Mutated NSCLC

Glecirasib has demonstrated activity in a phase 2 trial of patients with KRAS G12C-mutated, advanced NSCLC. Glecirasib has demonstrated activity in a phase 2 trial of patients with KRAS G12C-mutated, advanced NSCLC.

Related Keywords

China ,Beijing ,Chinese ,Yuankai Shi ,Chinese Academy Of Medical Sciences ,Chinese Academy ,Medical Sciences ,